<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01011634</url>
  </required_header>
  <id_info>
    <org_study_id>H10873-28990-01</org_study_id>
    <nct_id>NCT01011634</nct_id>
  </id_info>
  <brief_title>Trial Comparing Intravenous and Oral Moderate Sedation for First Trimester Surgical Abortions</brief_title>
  <official_title>A Double Blinded, Placebo-controlled Randomized Control Trial Comparing Intravenous Moderate Sedation and Oral/Sublingual Analgesia/Anxiolysis for First Trimester Surgical Abortions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the United States, the majority of first-trimester surgical abortions are performed in&#xD;
      outpatient clinics that utilize a wide variety of oral and intravenous regimens for pain&#xD;
      control. The specific aim of this study is to evaluate the equivalency of intravenous&#xD;
      moderate sedation (fentanyl 100 mcg and midazolam 2 mg) versus oral analgesia/anxiolysis&#xD;
      (lorazepam 2 mg sublingual, hydrocodone/acetaminophen 5/500 mg, and ibuprofen 800 mg) for&#xD;
      first-trimester surgical abortions. The investigators hypothesize that oral moderate sedation&#xD;
      and intravenous moderate sedation will be equivalent in controlling pain as measured by a&#xD;
      difference of +/- 10 on a 100-point (range 0-100) visual analog pain scale.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 50% of pregnancies in the United States are unintended and about 50% of these&#xD;
      end in an induced abortion. In 2000, approximately 1.31 million abortions were performed in&#xD;
      the United States, approximately 88% of which were less than 12 weeks gestational age. There&#xD;
      has been a movement toward performing elective abortions in the ambulatory care setting;&#xD;
      however this can provide a dilemma in terms of the procedural anesthesia. In fact, general&#xD;
      anesthesia for induced abortions has been associated with an increased incidence of&#xD;
      complications and death.5&#xD;
&#xD;
      The paracervical block (PCB) alone has been shown to reduce pain from cervical dilation and&#xD;
      tenaculum placement. Slower injection and greater volume have been associated with greater&#xD;
      pain control, possibly related to an effect on tissue distension as well as to nerve&#xD;
      blockade.6,7,8 However, women's perception of pain continues to be significant with PCB&#xD;
      alone.&#xD;
&#xD;
      A majority of high-volume first trimester providers (abortion clinics) offer intravenous&#xD;
      moderate sedation. However, many individual practitioners are limited in their ability to&#xD;
      provide outpatient moderate sedation, and research has shown mixed results about its&#xD;
      efficacy. There continues to be a dilemma in terms of what constitutes optimal anesthesia for&#xD;
      first trimester abortions to maximize pain control and minimize side effects and duration of&#xD;
      hospital/clinic stay for the patients. A randomized, double blind, placebo controlled trial&#xD;
      of intravenous fentanyl (50-100 mcg) with local anesthesia versus placebo and local&#xD;
      anesthesia alone in 368 participants found that fentanyl, when compared with placebo, reduced&#xD;
      the pain of first trimester abortion by 1.0 point on an 11-point verbal numerical scale. The&#xD;
      investigators concluded that this pain reduction was of questionable clinical significance&#xD;
      and less than what study participants desired (2.0 points). Another randomized, double blind,&#xD;
      placebo controlled study in 100 participants compared local anesthesia alone to local&#xD;
      anesthesia with intravenous fentanyl (25mcg) and midazolam (2mg) for first trimester suction&#xD;
      curettage. There was no statistically significant difference in pain scores between the&#xD;
      groups. However, patients who received intravenous sedation reported increased satisfaction&#xD;
      with their abortion procedure.11&#xD;
&#xD;
      There is some evidence of good pain control with oral and sublingual analgesia. Preliminary&#xD;
      data from a study performed at the UCSF Mt. Zion Women's Options Clinic between 11/04 and&#xD;
      12/05 (Meckstroth H10873-25519) of 120 women undergoing first trimester abortions who&#xD;
      received sublingual lorazepam, ibuprofen, and cervical block revealed that 84.5% of patients&#xD;
      reported their pain as acceptable during the procedure with 4.8% considering their pain level&#xD;
      unacceptable and 10.7% unsure.&#xD;
&#xD;
      Considering barriers to abortion access, developing an adequate medication regimen that does&#xD;
      not require the monitoring and expense of moderate sedation could be very helpful in&#xD;
      encouraging more providers to offer abortion. . Given that many patients pay directly for&#xD;
      abortions, increasing the cost of services can be prohibitive for many women. Oral&#xD;
      medications may also be more appealing to patients seeking sedation but who are fearful of&#xD;
      needles. We hope to demonstrate that pain will be adequately controlled with sublingual&#xD;
      lorazepam and oral ibuprofen- ideal medications for the clinic setting.&#xD;
&#xD;
      Currently, the standard of care in the SFGH Women's Option Center is moderate sedation with&#xD;
      IV fentanyl and midazolam. We will conduct a randomized control trial to evaluate moderate&#xD;
      sedation vs. sublingual lorazepam, oral ibuprofen, and hydrocodone/acetaminophen to assess&#xD;
      pain control and satisfaction in patients undergoing first trimester abortions. Both groups&#xD;
      will receive local cervical block analgesia.&#xD;
&#xD;
      The proposed study is a randomized, double-blind, controlled trial to be conducted at the San&#xD;
      Francisco General Hospital (SFGH) Women's Options Center evaluating the equivalency of&#xD;
      intravenous moderate sedation (fentanyl 100 mcg plus midazolam 2 mg) vs oral&#xD;
      analgesia/anxiolysis (lorazepam 2 mg sublingual, hydrocodone/acetominophen 5/500 mg, and&#xD;
      ibuprofen 800 mg) for first trimester surgical abortions.&#xD;
&#xD;
      The study participants will be derived from the SFGH Women's Options Center. On average, the&#xD;
      SFGH Women's Options Center performs about 2200 abortions per year, of which 50% are in the&#xD;
      first trimester, and intravenous moderate sedation is currently the standard pain control&#xD;
      regimen, utilized in nearly 100% of procedures. In the SFGH's sister clinic at Mt. Zion and&#xD;
      at Planned Parenthood Golden Gate and its affiliates, various regimes of oral&#xD;
      analgesia/anxiolysis are utilized instead. Both are considered standard of care for early&#xD;
      abortion both locally and nationally.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    7% enrollment. Study terminated after a small number of recruited patients&#xD;
  </why_stopped>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Score Within 5 Mins After Procedure</measure>
    <time_frame>within 5 mins after procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acceptability of Pain, Would They Choose the Same Regimen Again for Another Uterine Aspiration</measure>
    <time_frame>30 min after procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Undesired Intrauterine Pregnancy</condition>
  <condition>First Trimester Pregnancy</condition>
  <arm_group>
    <arm_group_label>Moderate sedation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral medication</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous moderate sedation versus oral medication</intervention_name>
    <description>Intravenous moderate sedation (fentanyl 100 mcg and midazolam 2 mg) versus oral analgesia/anxiolysis (lorazepam 2 mg sublingual, hydrocodone/acetaminophen 5/500 mg, and ibuprofen 800 mg)</description>
    <arm_group_label>Moderate sedation</arm_group_label>
    <arm_group_label>Oral medication</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Intrauterine pregnancy &lt;12 weeks gestation (as confirmed by ultrasound)&#xD;
&#xD;
          2. Ability to undergo outpatient abortion without an anesthesiologist&#xD;
&#xD;
          3. Age â‰¥ 16 years old&#xD;
&#xD;
          4. Informed consent prior to participation in study&#xD;
&#xD;
          5. English or Spanish language capacity (or staff or professional translator available&#xD;
             for all study procedures)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Possible ectopic pregnancy&#xD;
&#xD;
          2. Known allergy to study medications or misoprostol&#xD;
&#xD;
          3. Current unstable psychiatric disorder&#xD;
&#xD;
          4. Current alcohol/drug/narcotic/benzodiazepine/barbituate dependence within the previous&#xD;
             2 months&#xD;
&#xD;
          5. Weight &lt; 50 kg&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pratima Gupta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karen Meckstroth, MD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Francisco General Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>November 9, 2009</study_first_submitted>
  <study_first_submitted_qc>November 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2009</study_first_posted>
  <results_first_submitted>February 24, 2013</results_first_submitted>
  <results_first_submitted_qc>May 14, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 16, 2013</results_first_posted>
  <last_update_submitted>May 14, 2013</last_update_submitted>
  <last_update_submitted_qc>May 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>abortion</keyword>
  <keyword>uterine aspiration</keyword>
  <keyword>pain control</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Moderate Sedation</title>
        </group>
        <group group_id="P2">
          <title>Oral Medication</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Moderate Sedation</title>
        </group>
        <group group_id="B2">
          <title>Oral Medication</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>no baseline measurement as study stopped for low enrollment</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;= 18 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Acceptability of Pain, Would They Choose the Same Regimen Again for Another Uterine Aspiration</title>
        <time_frame>30 min after procedure</time_frame>
        <population>Study was stopped due to low enrollment (7%). No data analysis performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate Sedation</title>
          </group>
          <group group_id="O2">
            <title>Oral Medication</title>
          </group>
        </group_list>
        <measure>
          <title>Acceptability of Pain, Would They Choose the Same Regimen Again for Another Uterine Aspiration</title>
          <population>Study was stopped due to low enrollment (7%). No data analysis performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain Score Within 5 Mins After Procedure</title>
        <time_frame>within 5 mins after procedure</time_frame>
        <population>Study was stopped due to low enrollment (7%). No data analysis performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate Sedation</title>
          </group>
          <group group_id="O2">
            <title>Oral Medication</title>
          </group>
        </group_list>
        <measure>
          <title>Pain Score Within 5 Mins After Procedure</title>
          <population>Study was stopped due to low enrollment (7%). No data analysis performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Oral Medications</title>
        </group>
        <group group_id="E2">
          <title>IV Medications</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>.1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Karen Meckstroth, MD</name_or_title>
      <organization>UCSF</organization>
      <phone>415 206-8713</phone>
      <email>meckstrothk@obgyn.ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

